TY - JOUR
T1 - Correction to
T2 - Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases (Prostate Cancer and Prostatic Diseases, (2023), 26, 4, (743-750), 10.1038/s41391-022-00588-5)
AU - Schoen, Martin W.
AU - Carson, Kenneth R.
AU - Eisen, Seth A.
AU - Bennett, Charles L.
AU - Luo, Suhong
AU - Reimers, Melissa A.
AU - Knoche, Eric M.
AU - Whitmer, Alison L.
AU - Yan, Yan
AU - Drake, Bettina F.
AU - Sanfilippo, Kristen M.
N1 - Publisher Copyright:
© 2023, The Author(s).
PY - 2023/12
Y1 - 2023/12
N2 - Correction to: Prostate Cancer and Prostatic Diseases, published online 14 September 2022 The article Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases, written by, Martin W. Schoen, Kenneth R. Carson, Seth A. Eisen, Charles L. Bennett, Suhong Luo, Melissa A. Reimers, Eric M. Knoche1, Alison L. Whitmer, Yan Yan, Bettina F. Drake and Kristen M. Sanfilippo was originally published electronically on the publisher’s internet portal on 14 September 2022 without open access.
AB - Correction to: Prostate Cancer and Prostatic Diseases, published online 14 September 2022 The article Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases, written by, Martin W. Schoen, Kenneth R. Carson, Seth A. Eisen, Charles L. Bennett, Suhong Luo, Melissa A. Reimers, Eric M. Knoche1, Alison L. Whitmer, Yan Yan, Bettina F. Drake and Kristen M. Sanfilippo was originally published electronically on the publisher’s internet portal on 14 September 2022 without open access.
UR - http://www.scopus.com/inward/record.url?scp=85160668756&partnerID=8YFLogxK
U2 - 10.1038/s41391-023-00680-4
DO - 10.1038/s41391-023-00680-4
M3 - Comment/debate
C2 - 37253974
AN - SCOPUS:85160668756
SN - 1365-7852
VL - 26
SP - 811
JO - Prostate Cancer and Prostatic Diseases
JF - Prostate Cancer and Prostatic Diseases
IS - 4
ER -